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Abstract
Coxsackievirus B (CVB) infection is a common cause of acute viral myocarditis. The clinical presentation of myocarditis
caused by this enterovirus is highly variable, ranging from mildly symptoms to complete hemodynamic collapse. These
variations in initial symptoms and in the immediate and long term outcomes of this disease have impeded development of
effective treatment strategies. Nine cynomolgus monkeys were inoculated with myocarditic strains of CVB. Virological
studies performed up to 28 days post-inoculation demonstrated the development of neutralizing antibody in all animals,
and the presence of CVB in plasma. High dose intravenous inoculation (n = 2) resulted in severe disseminated disease, while
low dose intravenous (n = 6) or oral infection (1 animal) resulted in clinically unapparent infection. Transient, minor,
echocardiographic abnormalities were noted in several animals, but no animals displayed signs of significant acute cardiac
failure. Although viremia rapidly resolved, signs of myocardial inflammation and injury were observed in all animals at the
time of necropsy, and CVB was detected in postmortem myocardial specimens up to 28 days PI. This non-human primate
system replicates many features of illness in acute coxsackievirus myocarditis and demonstrates that myocardial
involvement may be common in enteroviral infection; it may provide a model system for testing of treatment strategies for
enteroviral infections and acute coxsackievirus myocarditis.
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Introduction
Viral infections are the most common etiology of acute
myocarditis. Parvovirus B19, human herpes virus 6, adenoviruses,
and the non-polio enteroviruses have been most frequently
implicated in recent studies [1]. Among the enteroviruses, the
group B coxsackieviruses (CVB) have historically warranted great
attention due to the age-dependent differences in the outcome of
acute infection. In the newborn period, these viruses often produce
life-threatening disease including meningoencephalitis, hepatitis,
sepsis and myocarditis [2,3,4]. Although the circulation of the
many serologic types of enteroviruses shows year to year variation
[2], a 2007 outbreak of cases of CVB type 1 (CVB1) in newborns
and other recent reports [5,6,7,8] demonstrate the ongoing threat
posed to newborns by myocarditic coxsackieviruses. In contrast,
older children and adults with enteroviral myocarditis typically
present with less severe initial disease and typically have better
long-term outcomes [9].
Mechanistic studies in inbred strain specific murine models have
suggested the possibility of progression from acute viral myocar-
ditis to chronic dilated cardiomyopathy after infection with CVB,
but confirmatory human data or demonstration of chronic viral
infection or latency in genetically heterogeneous animal models
are lacking [10,11,12]. Other animal models of myocarditis exist,
including the induction of autoimmune myocarditis in Lewis rats
by injection of myosin, and acute infection of pigs by encepha-
lomyocarditis virus (EMCV) [13,14]. However, EMCV is only
rarely a pathogen in humans, and the Lewis rat system does not
model the impact of viral replication in the myocardium and other
organs. Consequently, these systems are far from ideal models of
the acute pathophysiology and sequelae of enterovirus infection in
humans.
By contrast, non-human primates have many immunological
and physiological similarities with humans that might facilitate
their use in enterovirus research, including the structure and
function of immunoglobulins [15], organization of major histo-
compatibility antigen families [16], and cardiac physiology [17].
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CVB infection of non-human primates has been described in
several reports. In 1983, Hoshino et al described experimental
infection of 11 cynomolgus monkeys with CVB and detected
electrocardiographic changes and diffuse inflammatory infiltrates
in the myocardium, particularly in the right ventricle [18]. In
addition, there have been case reports of non-human primates
with naturally acquired infection of coxsackievirus and disease
similar to those in humans [19,20]. However, these reports
preceded the development of current virological and immunolog-
ical methods.
Natural history studies lack an accurate estimate of the
prevalence and severity of disease after infection with (versus
‘exposure to’) enterovirus. In this report, we describe the
prevalence of infection and myocarditis and immunological,
virological, and pathologic events seen following infection of
cynomolgus monkeys with two different strains of CVB, including
a strain well known to induce myocarditis in mice and a recently
identified strain from a case of fatal neonatal myocarditis [6].
These studies delineate a model for examination of virus-induced
pathology in non-human primates infected with cardiotropic
viruses. Such a model will be useful for preclinical and mechanistic
testing of potential treatment strategies.
Methods
Animals
Nine female cynomolgus monkeys (Macaca fascicularis) lacking
neutralizing antibody to coxsackievirus B3 (CVB3) were randomly
selected for use in this study. The animals ranged in age from 7.3
to 9.5 years and had body weights of 2.0 to 3.3 kg. All animals
were housed at the Tulane National Primate Research Center
(TNPRC). The TNPRC is an Association for Assessment and
Accreditation of Laboratory Animal Care accredited facility
(AAALAC #000594). The OLAW animal welfare assurance
number for TNPRC is A4499-01 and the USDA registration
number is 72-R-0002. The TNPRC animal care program follows
the laws and guidelines of the US Animal Welfare Act and the
NIH Guide for the Care and Use of Laboratory Animals. The
study presented in this manuscript was approved by the TNPRC
IACUC and by the Institutional Animal Care and Use Committee
of the University of California, Los Angeles.
Animal care at TNPRC is provided by a faculty of 8
veterinarians (7 ACLAM Diplomates), and 110 animal care
technicians, veterinary technicians, and enrichment staff. Animals
on this study were pair housed and received standard enrichment
which includes manipulable items in cage (durable and destruc-
table objects), perches or swings, various food supplements (fruit,
vegetables, primate treats), foraging or task- oriented feeding
methods, and human interaction with caretakers and research
staff. Monkeys are fed commercially produced chow twice a day.
Post IACUC approval monitoring including procedure evaluation,
assessment of technical skill and adherence to SOPs is assessed by
veterinary faculty and staff. Veterinarians are available 24 hours a
day to provide emergency care. The TNPRC Division of
Veterinary Medicine has established procedures to minimize pain
and distress through several means. The use of preemptive and
post procedural analgesia is required for procedures that would
likely cause more than momentary pain or distress in humans
undergoing the same procedure. Any deviation from the
administration of analgesics according to this policy requires
adequate scientific justification from the investigator and approval
by the IACUC. Tulane has a written endpoint policy to minimize
potential pain and distress experienced by animals. The policy
addresses limits on weight loss, appetite, tumor size, response to
medical intervention, activity, and a number of other clinical signs
relevant to laboratory animal species. If an animal becomes ill
and/or meets the criteria for the IACUC approved endpoint
policy, it is euthanized using methods consistent with recommen-
dations of the American Veterinary Medical Association (AVMA)
Panel on Euthanasia. Briefly, animals are anesthetized with
ketamine hydrochloride (10 mg/kg) and given an overdose of
sodium pentobarbital.
Virus Preparations
Infectious stocks of the myocarditic H3 strain of CVB3 were
produced by co-transfection of Hela cells with a plasmid clone of
the genome of this strain (pH3), along with a plasmid encoding T7
RNA polymerase (pAR3126), and titered on Hela-RW cells as
described by others [21,22,23]. A stock of CVB3-MCH (a
myocarditic isolate recovered from a case of fatal neonatal
myocarditis at Mattel Children’s Hospital (MCH) at UCLA in
2005 [6]) was prepared and titered using HeLa-RW cells. Animals
were infected by injection via the saphenous vein (8 animals) or by
enteral inoculation via an 8 French orogastric tube under
ketamine HCl anesthesia (1 animal).
Clinical evaluation
Animals were anesthetized with ketamine HCl prior to
inoculation with CVB3, and at each subsequent study point. At
each time point, transthoracic echocardiography was performed
using the LOGIQ Book XP (GE Healthcare, USA) with an 8 mhz
transducer. Wall motion was qualitatively examined by 2-
dimensional images in the parasternal long and short axis (below
the mitral valve) views and ejection fraction and fractional
shortening were measured by M mode in the parasternal short
axis view at the level of the mitral valve leaflets. Additional views
were examined when images were of sufficient quality. While
anesthetized, venous blood samples were drawn for complete
blood count, liver function tests, creatine phosphokinase (CPK),
blood glucose, assessment of serum neutralization antibodies, and
detection of CVB3 by culture and RT-PCR. Following infection,
the animals were monitored daily for activity level and appetite.
Body temperature was measured on days when the animals were
anesthetized. Point of care measurement of troponin I, B-type
natriuretic peptide (BNP) and CPK-MB fraction were performed
on plasma and serum using the Biosite Triage BNP Test (Biosite
Inc., San Diego, CA) (Limits of detection for these analytes were as
follows: TNI, 0.05 ng/ml; BNP: 5 pg/ml; and CPK-MB 1 ng/
ml). Plasma specimens TNI levels were later reexamined using a
monkey TNI ELISA assay kit (Life Diagnostics Inc., West Chester,
PA) with a sensitivity level of 0.15 ng/ml. All measurements were
repeated 3, 7, 14 and, in some cases, day 28 post-inoculation.
Detection of CVB Neutralizing antibody
CVB3-specific antibody levels in the serum of the animals were
determined by a microneutralization assay. Fourfold dilutions of
heat-inactivated serum from each time point were prepared
ranging from 1:10 to 1:163,840 and added to an equal volume of
virus containing 150 plaque forming units (pfu) of CVB (H3) was
added to the wells of a 96 well plate. After incubation at 37uC for
2 hours, Hela-RW cells were added to each well (50,000 cells in
200 ml of medium). After 48 hours, the wells were examined, and
the neutralizing antibody titer was designated as the highest
dilution that prevented the development of cytopathic effect
(CPE).
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Quantitative RT- PCR detection of CVB RNA
RT-PCR was performed for CVB3 RNA in plasma collected at
day 3, 7 and 14 post-inoculation (PI) and cardiac tissue samples
obtained at the time of necropsy in all infected animals. Viral
RNA was purified from 140 to 280 microliters of plasma using
QiAmp Viral RNA mini kit (Qiagen, USA) as specified the
manufacturer. Fresh frozen cardiac tissue was homogenized in
TRIzol reagent (Invitrogen Life Technologies Inc., USA), and
total RNA was extracted. The concentration of total RNA was
determined by spectrophotometery. cDNAs were generated by
reverse transcriptase reaction using random hexamer primers, and
CVB sequences were amplified and quantified by Real Time RT-
PCR as described by others [24] using serially diluted in vitro
transcribed CVB3 RNA as quantitative standards. The limits of
detection were approximately 17,000 copies of CVB3 RNA/ml
plasma.
Detection of infectious virus in cynomolgus monkey
plasma and cardiac tissue
Frozen plasma specimens from each time point were thawed,
vortexed, and added to HeLa-RW cell culture. Frozen fragments
of cardiac tissue were thawed, resuspended in tissue culture
medium, and mechanically disrupted using a Mini-Beadbeater-1
(Biospec, Bartlesville, OK). Clarified supernatants were added to
HeLa-RW cells, incubated for 24 to 72 h at 37uC and observed for
characteristic CPE. All cultures were also blindly passaged by
scraping the cells in each well into the overlying medium. After
three freeze-thaw cycles, the lysates were clarified by centrifuga-
tion and added to new cell cultures. After 48 hours incubation at
37uC, the cultures were again examined to detect the presence of
CPE.
Plasma Cytokine Evaluation
The concentration of plasma cytokines in frozen plasma samples
was performed using a Luminex multiplex cytokine assay
(Millipore) to detect cynomolgus IL1-beta, IL-1ra, TNF-alpha,
IFN-gamma, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40),
IL-13, IL-15, IL-17, IL-18, the chemokines MCP-1, MIP-1 alpha,
MIP-1 beta, as well as VEGF, G-CSF,GM-CSF, CD40L, and
TGF- alpha. The limit of detection for each analyte was 1 to 3 pg/
ml.
Pathologic evaluation: histology and
immunohistochemistry
Animals were sacrificed at the times indicated. Necropsy was
performed on all animals used in the study. Complete histological
examination of all major organs was performed. For immunohis-
tochemical evaluation paraffin-embedded sections were stained
using the Dako Autostainer (Dako Inc., Carpenteria CA). The
primary antibodies used included polyclonal anti-CD3 rabbit
serum (Dako Inc. Carpinteria CA),and mouse anti-human anti-
CD4 (Vector, Burlingame, CA) CD8 (Leica Microsystems,
Bannockburn, IL), CD68 (Dako, Inc. Carpinteria CA) and
CD20 (BD Biosciences, San Jose CA). For all primary antibodies,
slides were subjected to an antigen retrieval step consisting of
incubation in AR10 (Biogenex Inc, San Ramon, CA) for 2 min at
123uC followed by cooling to 90uC before rinsing in running water
and a final buffer rinse. Primary antibodies were replaced by
normal rabbit (Zymed Inc., South San Francisco CA) or mouse
IgG (Dako, Inc., Carpinteria CA) and included with each staining
series as the negative control. Binding of the mouse antibody was
detected using EnVision anti-mouse polymer (Dako, Inc. Carpin-
teria CA) or biotinylated sheep anti-rabbit IgG (Vector Lab Inc.),
Streptavidin-HRP (Invitrogen Inc. Grand Island NY) and DAB
(Dako Inc. Carpinteria CA). All slides were counterstained with
hematoxylin. Control experiments gave appropriate results with
minimal non-specific staining.
Results
Disseminated disease after high dose intravenous
inoculation
We initially infected two animals by intravenous injection of 107
pfu of H3, a strain of CVB3 known to be myocarditic in mice
[22,23]. Inoculation with this quantity of another strain of CVB
was previously shown to produce infection in 70% of nonhuman
primates (both baboons and cynomolgus monkeys) [18,25]. These
two animals developed signs of illness by 7 days PI, including
anorexia and decreased activity. One animal (FP49) was found to
be hypothermic, bradycardic, and moribund on day 11, and was
euthanized. The second animal (FP42) was euthanized at day 14 to
look for evidence of virus induced pathology.
Both animals were viremic on the third day PI, as demonstrated
by both RT-PCR and culture (Figure 1, Table 1). They developed
neutralizing antibody by day 7, and plasma viral cultures were
negative on day 7 and the day of euthanasia. Necropsy revealed
myocarditis, as expected, but there was also histological evidence
of meningitis, encephalitis, pancreatitis, and hepatitis in both
animals (Figure 2). Thus, in these animals, CVB3 infection
produced disseminated illness, similar to that seen following CVB
infection of newborn infants. Although there was clear histological
evidence of myocarditis at necropsy, cardiomegaly was not noted
and no significant echocardiographic or electrocardiographic
abnormalities were found, apart from minor transient wall motion
abnormalities (localized segmental hypokinesis) noted in FP49 on
the third day following infection. Ejection fraction and shortening
fraction measurements remained unchanged from baseline.
Neither animal had detectable plasma concentrations of TNI or
BNP at baseline or the day of euthanasia.
Myocardial injury and subclinical disease following low
dose intravenous CVB3 infection
In view of the severe illness observed in the initial pair of
animals, the viral inoculum was reduced ten-fold to 106 pfu, and
three monkeys (FP41, FP44, and FP46) were infected by
intravenous injection of CVB3-H3 and euthanized either 14 days
(FP41, FP44) or 28 days later (FP46). At this dose, viremia was
demonstrated in only one of these animals, and none developed
signs of illness after inoculation. Nonetheless, all three had
evidence of myocardial injury at the time of necropsy (Figure 3,
Table 1). In FP41 there were foci of vasculitis and myocarditis as
well as localized hypertrophy and myocytes with enlarged nuclei.
In FP44 myocardial findings included hypertrophic myocytes,
areas of inflammation without necrosis, and foci of lymphocytic
myocarditis (inflammatory infiltrates and injury to myocytes).
FP46 had similar evidence of inflammation, hypertrophy, and
ischemia at the time of necropsy (28 days PI). CVB RNA was
detected in the myocardium of FP44 and FP46 at 14 and 28 days
after infection respectively. TNI and BNP were not detected in the
plasma of either of these animals at any time point, but both had
echocardiographic evidence of minor wall motion abnormalities
only on day 3 PI. Ejection fraction and shortening fraction
remained unchanged from baseline.
To determine if other myocarditic strains would produce similar
pathology, three additional animals (FN16, FN20, FP47) were
injected with 106 pfu of CVB3-MCH, a strain recovered in 2005
from a newborn infant that died of myocarditis [6]. CVB3 RNA
Experimental Enteroviral Myocarditis in Primates
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was detected in plasma from all three on the third day after
inoculation, and two had positive plasma viral cultures as well
(Table 1). The animals were euthanized four weeks after
inoculation. Histological abnormalities found in cardiac tissue at
necropsy included focal cellular infiltrates in the myocardium of
FP47 (Figure 3, panel D), an area of ischemic change in FN 16 and
myocyte hypertrophy in FN 20 (not shown). CVB genomes were
not detectable by PCR in these animals and all other organs
examined were free of significant pathologic lesions at the time of
necropsy (day 28 PI). However, CVB-MCH was detected by viral
culture of tissue from the left ventricle of FP47 when necropsy was
performed on day 28 post-infection.
CPK, lactate dehydrogenase (LDH), and alanine aminotrans-
ferase (ALT) were measured in all six animals infected with either
low dose CVB3-H3 or CVB3-MCH (Figure 4). The serum ALT
increased in all but one animal during the period of follow-up; a
two fold elevation was typically seen. All animals developed an
increase in both serum CPK and LDH, reaching their maximum
observed values by day 7 and 14, respectively. Isozyme
fractionation of LDH was not performed. FP41 and FP44 both
had histologic evidence of hepatitis and FP41 had minimal focal
pancreatitis at necropsy (not shown). FP46 had normal histologic
findings in the liver, similar to those animals infected with high
dose virus and examined on days 11 or 14 PI. In contrast, none of
the animals euthanized on day 28 had histologic evidence of
hepatitis after infection with either virus.
CVB3 infection after enteral inoculation
In addition to the eight animals infected by intravenous
injection, one animal (FP43) was inoculated with 107 pfu of
CVB3-H3 by placing half of the virus suspension in the
oropharynx, and half in the stomach via a feeding tube. Viremia
was also demonstrated in this animal on day 3, and CVB3 RNA
was detected in the left atrium at 14 days PI when the animal was
euthanized (Table 1). Histopathologic findings included scattered
areas of myocytolysis and contraction band necrosis in the heart as
well as evidence of multifocal lymphocytic hepatitis (not shown).
Figure 1. Coxsackievirus viral load (plasma viral RNA copies/ml) (dashed lines) and neutralizing antibody titers (reciprocal of
dilution) (solid lines) after intravenous infection of two cynomolgus monkeys: FP42 (closed figures) and FP49 (open figures).
doi:10.1371/journal.pone.0074569.g001
Table 1. Summary of Animals and Virologic Studies.
Animal Virus
Inoculum
(pfu) Route
Euthanized
(study day)
CVB3 RNA
(copies/ml plasma)1
Plasma
Culture
RT-PCR
Cardiac Tissue2
FP42 CVB-H3 107 IV 14 4.56107 + -3
FP49 CVB-H3 107 IV 11 2.76106 + LV,RV,
FP41 CVB-H3 106 IV 14 - - LV,RV
FP44 CVB-H3 106 IV 14 1.06106 + RV
FP46 CVB-H3 106 IV 28 - - RA,RV
FP43 CVB-H3 107 Enteral4 14 8.16105 + LA
FP47 CVB-MCH 106 IV 28 5.56104 - -
FN16 CVB-MCH 106 IV 28 3.86106 + -
FN20 CVB-MCH 106 IV 28 4.06105 + -
1. Limit of detection approximately 10,000 copies/ml. ‘‘-‘‘ = not detected.
2. Viral RNA detected in tissue from chamber designated. LA = left atrium, RA = right atrium, LV = left ventricle, RV = right ventricle.
3. Only RV, LV, and RA tissue available from this animal.
4. See text for description.
doi:10.1371/journal.pone.0074569.t001
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Immunohistochemistry
Myocardial specimens containing inflammatory foci were
subjected to immunohistochemical analysis to determine charac-
teristics of cellular infiltrates. Examination of tissue from the right
atrium of one animal infected with high dose virus (FP42)
demonstrated a predominantly mononuclear infiltrate containing
CD3 cells with CD4 and CD8+ T cells approximately equally
represented. Monocytes were present in the infiltrate and in areas
surrounding it. B cells were nearly absent from the infiltrate and
surrounding myocardium (Figure 5). Inflammatory infiltrates from
other animals (FP49, FP41, FP44, FP46) infected with both high
and low dose of virus and examined at 14 or 28 days revealed
similar results: infiltrates consisting of a combination of CD4+ and
CD8+ T cells in equal proportions, many macrophages within the
infiltrate and scattered around injured myocardium, and a near
complete absence of B cells.
Immunological and Virological Analysis
As noted above, viremia was demonstrated by culture of plasma
collected on the third day after inoculation in 6 of 9 animals;
cultures of plasma on all subsequent time points were negative.
RT-PCR demonstrated the presence of CVB3 RNA in plasma in
7 of 9 animals on Day 3 PI. All 9 animals developed neutralizing
antibody by day 7 with titers ranging from 1:10 to 1:160, (data not
shown) and none had evidence of viremia by either RT-PCR or
culture at day 7 or at subsequent timepoints, except FP42 (Figure
1). This animal had the highest level of viremia at day 3 and viral
RNA was again detected in plasma on day 7.
Multiplex cytokine assays were used to examine changes in the
plasma concentration of proinflammatory and immunomodulato-
Figure 2. Postmortem histopathologic findings (hematoxylin-eosin (H&E) stain) of two cynomolgus monkeys injected with 107 pfu
of CVB3-H3. Myocardium from both FP42 (A (200X)) and FP49 (D (200X)) showed evidence of viral myocarditis, consisting of focal predominantly
lymphocytic mononuclear inflammatory infiltrates with myocyte injury. In addition, representative sections of the liver from both animals exhibited
changes of mild viral hepatitis including focal mononuclear inflammatory infiltrates within the hepatic lobules (B (FP42)) and portal tracts with
associated interface hepatitis (E (FP49)). The central nervous system exhibited perivascular lymphocytic infiltrates within the leptomeninges (C (FP42))
and intracerebral blood vessels (F (FP49)) with microglial proliferation and nodules (not shown). These changes are indicative of viral meningitis and
encephalitis (meningoencephalitis).
doi:10.1371/journal.pone.0074569.g002
Figure 3. Histopathological changes in the myocardium of
animals infected with CVB-H3 (FP41, FP44, and FP46) and
CVB3-MCH (FP47). FP41 (A) exhibiting prominent cytoplasmic
vacuolization indicative of myocytolysis (400X; H&E stain). FP44 (B)
revealing focal, predominantly lymphocytic, mononuclear inflammatory
infiltrate with associated myocyte injury consistent with myocarditis
(400X; H&E stain). FP46 (C) showing hypereosinophilic, hypercontracted
myofibrils indicative of contraction band necrosis of cardiac myocytes
(right lower corner) (400X; H&E stain). FP47 (D) demonstrating focal
mononuclear inflammatory infiltrate without associated myocardial
injury (400X; H&E stain).
doi:10.1371/journal.pone.0074569.g003
Figure 4. Biomarkers measured in animals inoculated with low
dose (106 pfu) CVB-H3 or CVB-MCH. Serum, unfractionated LDH
(&), total CPK (N), and ALT (%) are represented as mean +/2 SEM for
all 6 animals at each timepoint.
doi:10.1371/journal.pone.0074569.g004
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ry cytokines and chemokines and their relationship to plasma
viremia. Most of the 23 analytes were undetectable or present at
low, constant concentrations in plasma throughout the period of
observation. Striking changes in the plasma concentration of the
proinflammatory cytokines IL-6, TNFalpha, and interferon
gamma were identified in the animals infected with CVB3-H3
by high dose intravenous inoculation (FP42 and FP49). Peak
plasma cytokine concentrations were present on day 7 (Figure 6).
Only one of the animals given low dose or oral inoculation (FP41)
exhibited significant changes in any of the plasma cytokines
evaluated, despite the near uniform presence at necropsy of
histological changes indicative of myocardial injury as well as
hepatic injury in those animals examined by day 14.
Discussion
In this report we describe the clinical and histopathologic
characteristics of acute infection of non-human primates with
myocarditic strains of CVB. High dose intravenous inoculation of
cynomolgus monkeys resulted in severe, disseminated disease in
which a brief period of viremia was followed by encephalitis,
myocarditis, and other foci of infection, mimicking the pattern of
disseminated disease seen in neonatal infection [2]. By contrast,
oral or low dose intravenous inoculation of either strain of CVB3
studied resulted in subclinical illness that included evidence of mild
hepatitis and a variety of patterns of myocardial injury. No visible
myocardial scars or evidence of either ventricular enlargement or
myocardial thickening was observed during necropsy. While
inflammatory lesions are commonly encountered in the subendo-
cardial or supepicardial tissue in cynomolgous monkeys [26],
inflammation or definite myocarditis (as defined by the Dallas
Criteria [27]) were present in most animals (FP42, FP49, FP41,
FP44, FP46, FP47). Other myocardial abnormalities were also
noted, including myocytolysis, contraction band necrosis, and
hypertrophy of either myocytes or myocyte nuclei. Inflammatory
infiltrates consisted of CD4+ and CD8+ T cells with many
macrophages and were similar in tissues from animals examined at
2 or 4 weeks after infection. These processes appeared to affect
only a small area of the myocardium. Although we did not
examine cytokine levels in the myocardium, this may explain why
plasma cytokine levels only changed substantially in the two
animals infected with high-dose CVB3.
Our experience provides evidence of CVB persistence in the
myocardium. Inoculation of cynomolgus monkeys with 106 pfu of
either of the myocarditic strains of CVB3 was followed by rapid
resolution of viremia (demonstrated by RT-PCR detection of viral
RNA) and subclinical infection. Nonetheless, clearance of CVB
from the primate myocardium was protracted, with CVB RNA
detected in the myocardium of 5 of 9 animals at 14228 days, and
recovery of virus by culture from one animal (FP47) at 28 days PI.
It may be argued that detection of only positive strand RNA from
enterovirus is not incontrovertible evidence of persistent infection,
but the characteristics of replication of these viruses make
detection of negative strand difficult: The ratio of positive to
negative strand RNA during is 100 fold per replication cycle
making it exceedingly difficult to assure detection of negative
strand without contamination by positive strand [28]. Further-
more, one animal had a positive culture from myocardial tissue,
providing direct evidence of persistent viral infection.
Our understanding of the natural history of viral myocarditis in
humans is incomplete. In the short term, patients with fulminant
myocarditis may present with dramatic clinical symptoms, but
generally have a good long-term prognosis if supportive therapies
allow survival in the face of hemodynamic instability [29,30].
Based on murine models and case reports, it has been proposed
that dilated cardiomyopathy may begin with mild, perhaps
unrecognized, enterovirus infections followed by persistence of
enteroviral genomes and viral replication in the myocardium,
leading to injurious inflammation [31,32,33,34,35]. In addition,
some studies have suggested that chronic heart failure and dilated
cardiomyopathy may result from subclinical myocarditis and viral
persistence based on the presence of viral genomes in diseased
heart specimens (10,11 and reviewed in [36]). Our model provides
some support for this hypothesis. The consistent appearance of
myocardial pathology in our model makes it useful for investigat-
ing these hypotheses and preclinical testing of treatments aimed at
preventing the most severe, and often fatal, complications of
infection with enteroviruses. This model may also be useful to
examine differences in the pathogenicity of different CVB strains.
For example, we noted that the CVB3 RNA was detected in the
plasma in all three animals infected with CVB3-MCH, compared
to only 1 of 3 monkeys infected with a comparable intravenous
inoculum of CVB3-H3 (Table 1). By contrast, CVB3_RNA was
detected in the myocardium of all three animals infected with
CVB3-H3, versus only none of the animals receiving CVB3-
MCH. Additional experiments would be needed to confirm these
initial results in monkeys, but they are consistent with our having
seen a higher morality rate in mice infected by intraperitoneal
injection of the MCH strain, compared to the H3 variant [6].
Therapies for enteroviral infection and viral associated cardio-
myopathy are limited, and development of these therapeutic
approaches has been inhibited by the heterogeneous presentation
of enteroviral infection and myocarditis in clinical practice.
Murine models are useful, but concerns may be raised about the
relevance of murine models to myocarditis in humans. For
example, infection of BALB/c mice with myocarditic strains of
CVB commonly produces acute myocarditis and dilated cardio-
myopathy with lymphocytic infiltration of the myocardium, while
myocarditis is far less frequently observed after infection of C57Bl/
6 mice [10]. In our view, the non-human primate model we have
described represents a distinct advantage over murine models of
myocarditis, in which the outcome of infection is substantially
influenced by the strain of mouse chosen. The cardiac physiology
and of cynomolgous monkeys and non-human primates is also
comparable to humans, permitting the use of echocardiography
approaches employed in pediatrics. In addition, the immunoge-
netics of the major histocompatibility loci of cynomolgous
monkeys have been well studied, permitting detailed studies of
humoral and cellular immune responses [16].
Figure 5. Immunohistochemistry of myocardial tissue. Upper left
panel: H&E stain. Antibody specificity used for immunoperoxidase
staining is listed below remaining panels. (All sections at 400X)
doi:10.1371/journal.pone.0074569.g005
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As noted above, no antiviral agents are available for the
treatment of severe enteroviral infection, although a trial of
pleconaril [37,38] for the treatment of neonatal disease [Collab-
orative Antiviral Study Group Protocol 106] was recently
completed and is undergoing data analysis. However, a variety
of potentially useful compounds have been recently identified [38],
including our identification of fluoxetine and other existing
medications as inhibitors of CVB replication [39]. The impact
of these compounds on disease is so far untested but evaluation in
cynomolgous monkeys might prove useful for preclinical evalua-
tion of toxicity and antiviral activity.
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